| 23/07/26 | 11:05:13 | 23 Jul 2026 | | Notification of major holdings |
| 22/07/26 | 07:00:03 | 22 Jul 2026 | | Notification of Major Holdings |
| 21/07/26 | 07:00:04 | 21 Jul 2026 | | Notice of Allowance for POLB 001 patent in Israel |
| 14/07/26 | 07:00:05 | 14 Jul 2026 | | Placing to raise £3.5 million |
| 13/07/26 | 07:00:10 | 13 Jul 2026 | | First patient dosed in POLB 001 TOPICAL trial |
| 30/06/26 | 07:00:07 | 30 Jun 2026 | | POLB 001 patent granted in South Africa |
| 16/06/26 | 07:05:00 | 16 Jun 2026 | | European patent granted for POLB 001 in CRS |
| 16/06/26 | 07:00:06 | 16 Jun 2026 | | PDMR Notification |
| 11/06/26 | 07:05:01 | 11 Jun 2026 | | Preclinical data posters presented at EHA Congress |
| 11/06/26 | 07:00:07 | 11 Jun 2026 | | Poolbeg Announces POLB 001 TOPICAL Site Activation |
| 09/06/26 | 14:32:06 | 9 Jun 2026 | | Results of AGM & Change of Registered Address |
| 26/05/26 | 07:00:17 | 26 May 2026 | | Pre-IND Meeting with the FDA for POLB 001 |
| 13/05/26 | 07:00:06 | 13 May 2026 | | POLB 001 poster to be presented at EHA 2026 |
| 11/05/26 | 07:00:10 | 11 May 2026 | | POLB 001 CRS patent granted in Canada |
| 07/05/26 | 07:00:08 | 7 May 2026 | | Annual Report & AGM Notice |
| 28/04/26 | 07:00:06 | 28 Apr 2026 | | Results for the year ended 31 December 2025 |
| 15/04/26 | 07:00:08 | 15 Apr 2026 | | MHRA grants CTA for the POLB 001 TOPICAL trial |
| 31/03/26 | 07:00:14 | 31 Mar 2026 | | Significant milestone for Poolbeg's IP portfolio |
| 12/03/26 | 07:00:13 | 12 Mar 2026 | | Appointment of Dr Adrian Kilcoyne to SAB |
| 09/02/26 | 15:13:45 | 9 Feb 2026 | | Notification of Major Holdings |
| 28/01/26 | 07:00:09 | 28 Jan 2026 | | POLB 001 LPS Challenge Trial Paper Published |
| 27/01/26 | 14:30:14 | 27 Jan 2026 | | Exercise of Options & Total Voting Rights |
| 18/12/25 | 07:00:09 | 18 Dec 2025 | | Letter to Shareholders – 2025 a year of progress |
| 08/12/25 | 07:00:11 | 8 Dec 2025 | | POLB 001 to feature in CRS research programme |
| 20/11/25 | 07:00:15 | 20 Nov 2025 | | POLB 001 European Patent granted |
| 29/09/25 | 07:00:06 | 29 Sept 2025 | | Interim Results for the six months to 30 June 2025 |
| 25/09/25 | 07:00:05 | 25 Sept 2025 | | POLB 001 Phase 2a Trial Update |
| 01/07/25 | 16:24:49 | 1 Jul 2025 | | Notification of Major Holdings |
| 26/06/25 | 07:00:10 | 26 Jun 2025 | | Notification of Major Holdings |
| 25/06/25 | 08:00:00 | 25 Jun 2025 | | Director/PDMR Shareholding |
| 23/06/25 | 14:57:42 | 23 Jun 2025 | | Results of GM and AGM Meetings |
| 27/05/25 | 07:01:01 | 27 May 2025 | | FDA Orphan Drug Designation granted for POLB 001 |
| 27/05/25 | 07:00:15 | 27 May 2025 | | Annual Report, AGM Notice & Circular |
| 23/05/25 | 07:00:06 | 23 May 2025 | | Result of upsized oversubscribed BookBuild Offer |
| 22/05/25 | 13:44:08 | 22 May 2025 | | Increase of BookBuild Offer |
| 20/05/25 | 12:26:22 | 20 May 2025 | | Result of Placing and Notice of General Meeting |
| 20/05/25 | 07:02:00 | 20 May 2025 | | Proposed Retail Offer to raise up to £100,000 |
| 20/05/25 | 07:01:01 | 20 May 2025 | | Proposed Fundraising to raise approximately £4.1M |
| 20/05/25 | 07:00:09 | 20 May 2025 | | Results for the year ended 31 December 2024 |
| 27/03/25 | 07:00:16 | 27 Mar 2025 | | Conference Participation in March & April 2025 |
| 20/03/25 | 07:00:13 | 20 Mar 2025 | | POLB 001 Patent Granted in Korea |
| 25/02/25 | 08:50:44 | 25 Feb 2025 | | Form 8.5 (EPT/NON-RI) |
| 24/02/25 | 08:48:09 | 24 Feb 2025 | | Form 8.5 (EPT/NON-RI) |
| 21/02/25 | 07:00:04 | 21 Feb 2025 | | Termination of proposed combination with HOOKIPA |
| 20/02/25 | 09:03:58 | 20 Feb 2025 | | Form 8.5 Poolbeg Pharma Plc |
| 20/02/25 | 08:53:38 | 20 Feb 2025 | | Form 8.5 (EPT/NON-RI) |
| 18/02/25 | 17:35:15 | 18 Feb 2025 | | Holding(s) in Company |
| 18/02/25 | 17:04:30 | 18 Feb 2025 | | Form 8.3 - Poolbeg Pharma plc |
| 14/02/25 | 09:11:53 | 14 Feb 2025 | | Form 8.5 Poolbeg Pharma Plc |
| 13/02/25 | 10:30:05 | 13 Feb 2025 | | Form 8.5 Poolbeg Pharma Plc |
